About the Security (NASDAQ: MRNA)
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily Messenger RNA vaccines (mRNA).
Stock background:
Moderna shares have soared over 100% so far this week – an unprecedented rise in a single week after the company announced that its personalized mRNA cancer therapy, developed with Merck, cut the risk of recurrence and spreading.
The jump in shares highlighted this could be a game-changer in cancer treatment/therapy, and that the company could be embarking on the next leg higher from the Covid-led phase. The stock jumped 170% on a single day after the company made the announcement, adding over $40 billion in market value.
With this week’s rise, MRNA shares are up around 300% since this column highlighted the possibility of an uptrend. For more details, see “Moderna: Breaks Higher After Preliminary Earnings,” dated 22 January 2026.
Moderna (Weekly chart):
Technical Analysis on Moderna (NASDAQ: MRNA)
Once again, our TradersGPS (TGPS) system was early to pick the trend back in December 2025. It may sound like blowing our own trumpet, but we are in awe of the system!
The system remains bullish on MRNA, turned decidedly bullish on the weekly charts at the end of 2025. As per our system, Blue candles indicate the stock’s trend is up. Red candles indicate the trend is down.
Regular followers of this column would know that a signal on the weekly timeframe tends to have implications for the trend over a multi-month timeframe, which can be ideal for passive investors.
Moderna (Weekly chart):
After quite a bit of back-and-forth, which can be a feature of grand reversals, MRNA has cleared significant resistance levels to hit a more than a two-year high. The ‘two-steps-forward-one-step-back’ nature of recovery was highlighted in our last update, “Moderna: Runs into Resistance, But No Sign of Reversal,” published 1 July 2026.
The stock had been struggling to clear a stiff barrier at the October 2023 low of 62.50. Subsequent break of the resistance cleared the way for the 2024 high of 170.
What’s next in store? A massive jump in a short span argues for some consolidation at the very least. However, beyond the consolidation, if the stock manages to break past xxx, it would be a precursor to a major long-term bullish trend.
Trading Strategy:
In the previous update, we highlighted that it would make sense to hold on to longs while the candle colour remains Blue. Indeed, the candle colour on the TGPS system remains Blue. Unfortunately, there was no chance of further dollar-cost-averaging as MRNA failed to dip below 50.
However, I underestimated the extent and the pace of the rally (See Moderna: Runs into Resistance, But No Sign of Reversal,” published 1 July 2026). The rally has surpassed my expectations and probably any template of a long-term rebound.
I would be inclined to take some cash off the table given the unprecedented rise. At the same time, I would retain 50% until the candle colour remains Blue on the TGPS system.
